Print

America Stem Cell, Inc. Awarded a Phase I SBIR to Explore the Therapeutic Potential of Its Platform Technology (ASC-101) with Neural Stem Cells in Multiple Sclerosis Model  
1/7/2013 10:25:33 AM

SAN ANTONIO--(BUSINESS WIRE)--America Stem Cell, Inc. (ASC) today announced that it has been awarded an Advanced Technology Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be led by Dr. Leonard Miller, VP Preclinical Research at ASC, in collaboration with Dr. Larry Sherman at the Oregon National Primate Research Center, Oregon Health & Science University (OHSU). Dr. Sherman’s lab has over 15 years of extensive experience in multiple models of demyelinating diseases such as multiple sclerosis (MS), and in the application of these models to identify novel therapeutic approaches. Furthermore, the first-ever transplants of human NSCs into human patients for Batten Disease, a demyelinating disease that affects children, were at Dr. Sherman’s Institute (OHSU).
//-->